All In Biotech

NDA 210858 · Ibsa

Vybrique

Sildenafil Citrate · Oral

Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Dec 16, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

439

87 Phase 3, 20 recruiting

FAERS reports

58,697

42,844 serious, 8,676 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 17, 2026.

1. INDICATION S AND USAGE SILDENAFIL ORAL FILM is indicated for the treatment of erectile dysfunction. SILDENAFIL ORAL FILM is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). ( 1 )

Mechanism: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 2025 Original approval · Type 3 - New Dosage Form LetterLabel
4 products under this application
  • VYBRIQUE · SILDENAFIL CITRATE EQ 100MG BASE · FILM, ORAL · Prescription
  • VYBRIQUE · SILDENAFIL CITRATE EQ 50MG BASE · FILM, ORAL · Prescription
  • VYBRIQUE · SILDENAFIL CITRATE EQ 75MG BASE · FILM, ORAL · Prescription
  • VYBRIQUE · SILDENAFIL CITRATE EQ 25MG BASE · FILM, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sildenafil" as an intervention, any sponsor and status, largest first.

All 439 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea8,090
  • headache6,073
  • diarrhoea4,714
  • nausea4,199
  • fatigue4,055
  • death4,027
  • dizziness3,520
  • drug ineffective3,249
  • cough3,224
  • pneumonia2,743
  • hypotension2,493
  • vomiting2,491

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004124
2005186
2006393
2007174
2008234
2009295
2010416
2011457
20121,172
20131,589
20142,307
20152,706
20163,100
20173,839
20184,222
20195,480
20205,142
20214,407
20224,449
20234,803
20244,904
20255,073
20263,225

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,255 on PubMed

Sponsor: Ibsa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.